Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Shares Sold by Natixis Advisors LLC

Natixis Advisors LLC lessened its stake in shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) by 12.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,826 shares of the company’s stock after selling 1,841 shares during the quarter. Natixis Advisors LLC’s holdings in Fresenius Medical Care AG & Co. KGaA were worth $319,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. GAMMA Investing LLC raised its position in Fresenius Medical Care AG & Co. KGaA by 34.0% in the 1st quarter. GAMMA Investing LLC now owns 9,603 shares of the company’s stock valued at $239,000 after purchasing an additional 2,439 shares during the last quarter. Cerity Partners LLC grew its stake in Fresenius Medical Care AG & Co. KGaA by 22.4% in the 1st quarter. Cerity Partners LLC now owns 39,903 shares of the company’s stock valued at $994,000 after acquiring an additional 7,299 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Fresenius Medical Care AG & Co. KGaA during the 4th quarter worth about $447,000. Point72 Asset Management L.P. acquired a new stake in shares of Fresenius Medical Care AG & Co. KGaA during the 4th quarter worth about $850,000. Finally, Forum Financial Management LP acquired a new stake in shares of Fresenius Medical Care AG & Co. KGaA during the 4th quarter worth about $247,000. Hedge funds and other institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Trading Up 0.3%

Shares of FMS stock opened at $24.19 on Wednesday. Fresenius Medical Care AG & Co. KGaA has a 12 month low of $18.42 and a 12 month high of $30.46. The company has a quick ratio of 1.08, a current ratio of 1.44 and a debt-to-equity ratio of 0.44. The business’s 50 day moving average is $26.97 and its two-hundred day moving average is $25.79. The company has a market cap of $14.20 billion, a PE ratio of 19.83, a price-to-earnings-growth ratio of 0.56 and a beta of 0.87.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last issued its earnings results on Tuesday, August 5th. The company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.50 by $0.02. The firm had revenue of $5.54 billion during the quarter, compared to analysts’ expectations of $5 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 6.75% and a net margin of 3.39%. Equities analysts predict that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on FMS. Truist Financial raised their target price on shares of Fresenius Medical Care AG & Co. KGaA from $25.00 to $30.00 and gave the stock a “hold” rating in a research report on Monday, May 12th. Morgan Stanley reaffirmed an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Tuesday. Finally, Wall Street Zen downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “buy” rating in a report on Saturday. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $27.80.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.